Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

iKang Receives $1.1 Billion Go-Private Offer

publication date: Sep 1, 2015

After a short eighteen months as a publicly owned company, iKang Healthcare is considering a go-private offer from a group led by its Founder/Chairman/CEO. iKang, headquartered in Beijing, operates private preventative healthcare clinics throughout China. The company raised $153 million in an IPO on the NASDAQ exchange in April 2014. Now, Mr. Ligang Zhang, the company's CRO, together with FountainVest, a China private equity firm, proposes to take the company private at $17.80 per ADS, a modest 10.8% premium from the most recent close and a 27% increase from the $14/ADS IPO price. The offer values iKang at $1.1 billion. More details....

Stock Symbol: (NSDQ: KANG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital